F. Orlandi

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC

MAKI NISHIO, Fabrice Barlési, S. Ball et al. · Annals of Oncology · 2020 · 12 citations · Full text

Medicine, Oncology, Pharmacology +8

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

Martin Reck, Robert M. Jotte, Tony Mok et al. · Annals of Oncology · 2019 · 11 citations

Medicine, Oncology, Pharmacology +14